<?xml version="1.0" encoding="UTF-8"?>
<p>The aim of this study was to evaluate the burden of confirmed RSV illness from midpregnancy to 24 weeks postpartum among cohorts of human immunodeficiency virus (HIV)â€“uninfected and HIV-infected black-African women to determine their potential benefit from maternal RSV vaccination aimed primarily at protecting their probands.</p>
